Bone metastasis is a complication of prostate cancer in up to 90% of men afflicted with advanced disease. Therapies that reduce androgen exposure remain at the forefront of treatment. However, most prostate cancers transition to a state whereby reducing testicular androgen action becomes ineffective. A common mechanism of this transition is intratumoral production of testosterone using the adrenal androgen precursor dehydroepiandrosterone through enzymatic conversion by 3b- and 17b-hydroxysteroid dehydrogenases. Given the ability of prostate cancer to form blastic metastases in bone, we hypothesized that osteoblasts might be a source of androgen synthesis. RNA expression analyses of murine osteoblasts and human bone confirmed that at least one 3bHSD and 17bHSD enzyme isoform was expressed, suggesting that osteoblasts are capable of generating androgens from adrenal DHEA. Murine osteoblasts were treated with 100 nM and 1 mM DHEA or vehicle control. Conditioned media from these osteoblasts were assayed for intermediate and active androgens by liquid chromatography-tandem mass spectrometry. As DHEA was consumed, the androgen intermediates androstenediol and androstenedione were generated and subsequently converted to testosterone. Conditioned media of DHEA-treated osteoblasts increased androgen receptor signaling, prostate-specific antigen production, and cell numbers of the androgen-sensitive prostate cancer cell lines C4-2B and LNCaP. DHEA did not induce androgen receptor signaling in osteoblasts despite androgen receptor expression in this cell type. We describe an unreported function of osteoblasts as a source of testosterone that is especially relevant during androgen-responsive metastatic prostate cancer invasion into bone.  Bone metastases occur in up to 90% of men with advanced prostate cancer compared with significantly lower rates of skeletal metastases from other common cancers such as lung and colon. The avidity of prostate cancer for bone suggests that the skeleton harbors factors in the bone microenvironment that foster prostate cancer growth. Although work in this area has identified potential skeletal-derived factors that include bone morphogenetic proteins, wingless-integrated (Wnt)-signaling ligands, insulin-like growth factors, and transforming growth factor-beta, none of these targets have shown promise to prevent and treat prostate cancer bone metastases.  The most well-known factors necessary for prostate cancer growth are androgens. This observation was the basis for the development of androgen-deprivation therapies to suppress testicular testosterone production. Androgen-deprivation therapies increase overall survival and progression-free survival in men with early castration-sensitive prostate cancer. Unfortunately, most androgen-deprivation therapy-treated disease evolves into castration-resistant prostate cancer, typically within 2 years after androgen-deprivation therapy initiation. A mechanism that castration-resistant prostate cancer cells commonly use to evade androgen-deprivation therapy is

the intratumoral synthesis of androgens from the abundant circulating adrenal precursor dehydroepiandrosterone (DHEA). DHEA is produced in the adrenal cortex and is therefore unaffected by conventional ADT.  Dihydrotestosterone (DHT) is the most potent circulating androgen and is synthesized from T by peripheral tissues, with an affinity for the androgen receptor (AR) two to three times greater than T. DHEA conversion to DHT requires three steroidogenic enzymes: 3b-hydroxysteroid dehydrogenase (3bHSD), 17b-hydroxysteroid dehydrogenase (17bHSD), and steroid 5a-reductase (SRD5a). Seven mouse and 3 human 3bHSD, at least 14 17bHSD (that includes proteins encoded by AKR1C3 in humans, Akr1c6 in mice, RDH5, and RDH11), and 3 SRD5a steroidogenic isoforms have been discovered, each with unique tissue expression patterns. Other groups have reported that osteoblasts express the three steroidogenic enzymes required for DHEA conversion to T and DHT. Both T and DHT bind AR, which results in AR dimerization and translocation to the nucleus. The active androgen-AR complex then binds to androgen-response elements (AREs) and activates the transcription of androgen-responsive genes.  Mouse osteoblasts and human bone express at least one isoform of 17bHSD and 3bHSD. The skeleton may therefore generate androgens from DHEA, which represents an important mechanism for preferential growth of prostate cancer in bone and the formation of blastic rather than lytic metastases. We now report a novel mechanism by which the osteoblast utilizes DHEA as a substrate for active androgen synthesis that fuels prostate cancer androgen signaling and growth. This paracrine function of osteoblasts has not been reported previously and represents another example that the skeleton is a hormone-producing organ.  Materials and Methods  Harvest of murine osteoblasts  For primary calvarial osteoblast cultures, calvariae were harvested from 4-day-old ICR Swiss mouse pups, washed in phosphate-buffered saline (PBS), and then placed in PBS (2 mL per mouse litter) containing 0.1% collagenase (Wako Pure Chemical Industries, Osaka, Japan) and 0.2% dispase (Roche Applied Science, Penzberg, Germany). Calvariae were agitated at 37째C for 7 minutes to release cells. The first extraction was discarded, and the process was repeated three times. Osteoblasts collected in the last three extractions were combined. Cells were plated at a density of 106 cells per 3.8 cm2 in aMEM, 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 mg/mL streptomycin.  Murine long bone osteoblasts were harvested using a modified protocol as previously described. Femora, tibiae, and humeri were harvested from 4- to 6-week-old mice and thoroughly cleaned with a scalpel. Whole bones were subjected to a 20-minute digestion in digestion buffer at 37째C with shaking. This digestion was discarded, and the bones were subsequently washed three times in PBS. Any remaining tissue attached to the bones was removed to eliminate any potential contamination of other musculoskeletal cells. The epiphyseal/metaphyseal regions of the cleaned bones were removed, cut into smaller pieces, washed twice with PBS, and digested 2 hours at 37째C with shaking. Dispersed cells from this digest were collected by centrifugation and plated in aMEM with 10% FBS containing 100 IU/mL penicillin, and 100 mg/mL streptomycin. Osteoblasts are routinely cultured in hypoxia (5% O2).  FBS that had been charcoal-stripped, a method to remove steroids, was used to culture osteoblasts during experimentation. Briefly, FBS was charcoal-stripped using a dextran-coated

charcoal protocol. Each batch completed this process three times to ensure maximum removal of steroids.  Alizarin red staining of cultured osteoblasts  Cells were thawed and plated in a six-well plate in aMEM with 10% FBS containing 100 IU/mL penicillin and 100 mg/mL streptomycin. The next day, half of the wells' media were treated with differentiation media containing osteoblast media with 10 mM beta-glycerol phosphate and 50 mg/mL ascorbic acid. Media from all wells were replaced every 3 days for 28 days. On the 28th day, the cells were washed carefully with PBS three times, fixed in 10% buffered formalin for 30 minutes, washed with distilled water twice, and stained with fresh 2% alizarin red (pH 4.2 with 10% ammonium hydroxide) for 5 to 10 minutes. The cells were carefully washed with copious amounts of water until no stain was observed in the wash.  RNA-Seq  Murine calvarial osteoblasts from 4-day-old ICR Swiss pups were harvested. These cells were plated in triplicate in six-well plates and grown to confluence. The cells were washed with PBS and frozen at -80 C. The RNA was isolated using a Zymo RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA). RNA integrity was evaluated using 0.1% bleach in a 1% agarose gel. RNA-Seq libraries were generated using the Illumina TruSeq Stranded mRNA prep kit (Illumina, San Diego, CA, USA) and paired-end sequenced on a NextSeq 500/550 (Illumina) using an Illumina Nextseq High Output 150 cycle v2 cartridge. The reads were aligned to the GRCm38 genome assembly with hierarchical indexing for spliced alignment of transcripts (HISAT2), then assembled and quantified with Stringtie. Genes with less than six reads and 0.1 transcripts per million (TPM) in more than two samples were filtered.  Real-time RT-PCR  Long-bone osteoblasts were cultured to confluence and RNA harvested using a Zymo RNA MiniPrep Kit (Zymo Research). Messenger RNA expression was determined by real-time RT-PCR using an iScript SYBR Green RT-PCR kit (Bio-Rad, Hercules, CA, USA) and a MyIQ Single-Color Real-Time PCR Detection System (Bio-Rad). Relative differences in mRNA concentration were determined by subtracting the Ct (threshold cycle) of the study gene from the Ct of the housekeeping gene Rpl32 (D = Ctgene-CtRPL32). The mean of the lowest enzyme isoform (Dlow) was subtracted from each cell type (Dsample); (mean Dlow - Dsample = e). The fold difference was calculated as 2e.  Cell lines and reagents  The prostate cancer cell lines C4-2B, LNCaP, and 22Rv1 were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). The C4-2B and 22Rv1 cell lines were cultured in RPMI 1640 with 2 mM L-glutamine growth medium supplemented with 10% FBS. The LNCaP cell line was cultured in the same media as above but with the addition of 1 mM sodium pyruvate. The ARCaPM prostate cell line was obtained from Novicure Biotechnology (Birmingham, AL, USA) and cultured in MCaP media (Novicure Biotechnology) supplemented with 5% FBS. All cell lines were also cultured with 100 IU/mL penicillin and 100 ml/mL streptomycin at 37 C containing 5% CO2. DHEA was obtained from Steraloids (Newport, RI, USA); R1881 was obtained from PerkinElmer (Waltham, MA, USA); and enzalutamide was obtained from Selleck.

Chemicals (Houston, TX, USA). During experimentation, charcoal-stripped FBS was used. Tandem mass spectrometry with two-dimensional liquid chromatography (LC-MS/MS) Unlabeled and deuterium-labeled steroid standards were obtained from Sigma-Aldrich (St. Louis, MO, USA), Cerilliant (Round Rock, TX, USA), C/D/N Isotopes (Pointe-Claire, Canada), and Cambridge Isotope Laboratories (Tewksbury, MA, USA). A 20-mL aliquot of conditioned medium was diluted with 80 mL deionized water, mixed with internal standards, and extracted with 0.7 mL methyl-tert-butyl ether using Isolute cartridges (Biotage, Charlotte, NC, USA). The 3-keto-delta-4-steroids and estrogens were quantitated directly using Agilent (Santa Clara, CA, USA) 1260 and 1290 dual front-end HPLC/UPLC equipped with 3 x 10 mm, 5-mm particle size C4 HypersilGOLD cartridge (Thermo Fisher, Waltham, MA, USA), Kinetex 150 mm x 2.1 mm, 2.6-mm particle size biphenyl resolving column (Phenomenex, Torrance, CA, USA), and an Agilent 6495 triple quadrupole mass spectrometer operating in electrospray ionization and multiple reaction monitoring (MRM) modes. The 3-hydroxy-delta-5-steroids were quantitated after liquid-liquid extraction with methyl-tert-butyl ether and derivatization as picolinic acid esters, using a Kinetex 50 x 2.1 mm, 2.6-mm particle size biphenyl resolving column and an Agilent 6490 tandem mass spectrometer.  Lentivirus transduction The lentivirus pBM14-tat3-g.luc-VSVG (tat3-GLuc) construct was a gift from Dr William Rainey. This reporter construct contains three AREs fused to a basal promoter and the Gaussia luciferase gene. The original tat3 AR reporter promoter was constructed previously. Gaussia luciferase (GLuc) is a secreted luciferase allowing for collection and assay of media. The University of Michigan Vector Core provided the lentivirus 3.7DsRed-VSVG that constitutively expresses Discosoma red fluorescent protein (DsRed). Lentivirus stocks were diluted to 1X in a minimal volume of media with 6 mg/mL of polybrene added to the cultured cells. At 50% confluent, cells were incubated with

the 1X lentivirus overnight. The next morning, cultures were replaced with fresh medium and allowed to recover for 24 hours before plating into experimental dishes.  AR-Gaussia reporter assay Cells transduced with the tat3-Gluc/DsRed lentivirus combination were plated into 24-well black-walled, glass-bottom plates at 50% confluence. The cells were treated in quadruplicate. When conditioned media were collected, DsRed fluorescence was determined from each well using a BioTek Synergy HTX plate reader (BioTek, Winooski, VT, USA), with the values used to normalize GLuc values. Conditioned media were collected and tested for GLuc activity using the GLuc substrate coelenterazine (Prolume, Pinetop, AZ, USA). A 12-mM coelenterazine master stock was made with acidified methanol and stored at -80째C. The master stock was diluted in PBS containing 5 mM sodium chloride to make a 30 mM working stock. Fifty microliters were injected into the wells of a solid white 96-well plate containing 20 mL of collected media from the transduced experimental cells. After a 2-second shaking, luminescence signal was integrated for 10 seconds and measured on a BioTek Synergy HTX plate reader (BioTek).  Prostate-specific antigen (PSA) enzyme-linked immunosorbent assay (ELISA) Cells were plated into 24-well black-walled, glass-bottom plates at 50% confluence. The cells were treated as with previous experiments in quadruplicate. PSA concentration of conditioned media was determined using human kallikrein 3/PSA Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) on days 2 and 3 after the treatment. When conditioned media were collected, cell number was determined from each well using a BioTek Lionheart FX automated microscope (BioTek) with the cell numbers, as measured by DsRed fluorescence, used to normalize PSA values.  Prostate cancer growth assays Prostate cancer cells with constitutive DsRed expression were plated into 24-well black-walled, glass-bottom plates at 10% confluence. The cells were treated as with previous experiments in quadruplicate with treatments replenished at day 3. At days 0, 3, and 6, each well was imaged using a BioTek Lionheart FX automated microscope (BioTek) with a 4x/0.13NA objective (Olympus, Tokyo, Japan) and an RFP filter cube (531 nm/593 nm) paired with a 523 nm high-power LED.

analyzed for confluency using the Gen5 Image Prime software package.  Statistical analyses Single-variable data sets containing two groups were analyzed by a t test. Single-variable data sets containing three or more groups were analyzed by one-way ANOVA. Data sets containing two independent variables were analyzed by two-way ANOVA using Dunnett's, Sidak's, or Tukey's multiple comparison testing. Data were analyzed using GraphPad Prism 9 Software. An a-cut-off value of 0.05 was used for all analyses and reported p values were applied to two-tailed analyses.  Results  Osteoblasts express androgen steroidogenic enzymes  To test the hypothesis that osteoblasts metabolize DHEA into active androgens, we first assessed the expression of the required enzymes for these conversions. The expression of each of these enzymes was determined using three complementary methods--RNA-Seq of cultured murine calvarial osteoblasts, RT-PCR of murine long-bone osteoblasts from male and female mice, and analysis of public RNA-Seq data from a human cohort of iliac crest bone biopsies from 58 healthy female subjects. At least one isoform of the three enzymes was expressed in the mouse and human samples. The patterns of HSD17B isoform expression were remarkably similar between the two murine and one human expression data sets, with HSD17B4, HSD17B10, HSD17B11, HSD17B12, and RDH11 having consistent expression across the three data sets. SRD5A1 and SRD5A3 were also expressed among the murine osteoblasts and human bone samples. A single gene isoform of HSD3B--HSD3B7--was abundantly expressed in mouse osteoblasts and human bone. Differences in expression between male and female long-bone osteoblasts were detected, although the overall pattern of isoenzyme expression remained the same. The striking similarities between mouse and human expression existed despite the likely presence of bone cells other than osteoblasts present in the human bone marrow samples. The expression of Cyp19a1, the gene that encodes aromatase that generates estradiol from T and estrone from androstenedione, was not detected in murine calvarial osteoblasts via RNA-Seq or long-bone osteoblasts via real-time RT-PCR expression analyses. Human CYP19A1 message was reported present in the iliac crest bone biopsy samples but in a very low amount with a mean gene count of 29.8. Gene counts of less than 10 were reported as being non-expressed. This level of expression was similar to other steroidogenesis genes with the lowest gene counts such as HSD17B3 and HSD17B6.  Osteoblasts generate active androgens from DHEA  Murine osteoblasts harvested from the epiphyseal region of long bones were selected for study. To assess osteoblast metabolism of DHEA, confluent murine osteoblast cultures were treated with 100 nM and 1 mM DHEA and compared with an ethanol vehicle control.

were collected 24, 48, and 72 hours later and analyzed by LC-MS/MS. As the DHEA concentration declined, androstenediol and androstenedione increased with peak concentrations of 36,716 and 253 pg/mL, respectively, at 48 hours with the 1 mM DHEA treatment. DHEA was preferentially converted to androstenediol, rather than androstenedione since the peak concentration of androstenediol was more than 10 times greater than androstenedione in both the 100 nM and 1 mM DHEA treatment groups. The peak concentration of T was 101 pg/mL at 72 hours with the 1 mM DHEA treatment. The synthesis of androstenedione from DHEA and T from androstenediol by the only 3bHSD enzyme expressed, 3bHSD7, may be a rate-limiting step in the conversion of DHEA to active androgens. Despite Srd5a expression, DHT was not detected with the 1 mM DHEA treatment at any time point.  Neither estradiol nor estrone was detected in DHEA-treated osteoblast conditioned media by LC-MS/MS. The lower limit of detection of these estrogens in this sensitive assay is 4.9 pg/mL and is consistent with negligible Cyp19a1 expression in murine osteoblasts.  Prostate cancer generation of androgens from DHEA  The prostate cancer cell lines LNCaP and C4-2B are androgen sensitive. The ability of these cell lines to generate androgens from DHEA was compared with two androgen-insensitive prostate cancer cell lines, 22Rv1 and ARCaPM. LNCaP, C4-2B, 22Rv1, and ARCaPM cells were transduced with a lentivirus expressing a constitutively active red fluorescent protein DsRed as a normalization control for any potential cellular proliferative effects of the treatments. After transduction, cells were treated with 100 nM DHEA. Media were collected 72 hours later and assayed for DHEA, androstenediol, androstenedione, T, and DHT by LC-MS/MS.  LNCaP and C4-2B cells demonstrated active 3bHSD activity with robust conversion of DHEA to androstenedione.

activity was detected in 22Rv1 and ARCaPM cells. Significant androstenediol was detected in 22Rv1 and ARCaPM, and less in C4-2B and LNCaP. C4-2B generated significant T followed by 22Rv1, LNCaP, and ARCaPM. DHT was only detected in C4-2B media. In contrast to 22Rv1 and ARCaPM, LNCaP and C4-2B cells efficiently metabolized DHEA.  Conditioned media of osteoblasts treated with DHEA activate prostate cancer AR signaling  The capacity for osteoblast-generated T to activate AR signaling in prostate cancer cells was next tested. Since the androgen-sensitive prostate cancer cells also synthesize androgens from DHEA, the contributions of each cell type to generate androgens were determined. Residual T already present in osteoblast conditioned media would immediately activate prostate cancer AR signaling, whereas DHEA must first be converted to T or DHT in prostate cancer cells before AR signaling would commence.  The prostate cancer cell lines LNCaP and C4-2B were transduced with a lentivirus AR-reporter construct containing three AREs fused to a basal promoter and Gaussia luciferase. GLuc is a secreted protein that allows for easy collection of media over time as a measure of androgen receptor signaling activation. The cells were also transduced with a lentivirus constitutively expressing DsRed, with fluorescence used to normalize GLuc values to relative cell number. The androgen analog R1881 robustly increased GLuc activity in both LNCaP and C4-2B prostate cancer cell lines. The ability of osteoblast conditioned media to activate prostate cancer AR signaling was next examined. CM was collected from murine long-bone osteoblasts 72 hours after treatment with 100 nM and 1 mM DHEA, or an ethanol vehicle control. More immediate increases in GLuc were expected from T already present in DHEA-treated osteoblast conditioned media compared with direct DHEA treatment of the prostate cancer cells. After prostate cancer cells were transduced with the tat3-Gluc/DsRed lentivirus combination, the media were replaced with 50% of the respective prostate cancer medium and 50% conditioned media from osteoblasts that had been treated with 100 nM DHEA, 1 mM DHEA, or ethanol vehicle control. These groups were compared with the prostate cancer cells treated directly with 100 nM DHEA, 1 mM DHEA, or ethanol vehicle control along with 50% osteoblast conditioned media treated with EtOH. As expected, the groups treated with ethanol vehicle conditioned media or ethanol vehicle directly did not show AR signaling activation.  In both LNCaP and C4-2B cell lines, treatment with 100 nM DHEA conditioned media versus 100 nM DHEA, and 1 mM DHEA conditioned media versus 1 mM DHEA resulted in significantly more AR signaling activation at 12, 24, 36, and 48 hours. Continued differences were detected in the LNCaP cell line at 72 hours. In the C4-2B cell line, 100 nM DHEA treatment at 72 hours resulted in even greater AR signaling activation compared with the 100 nM DHEA conditioned media group. At 1 mM DHEA conditioned media compared with 1 mM DHEA treatment, the degree of AR signaling activation was similar.  Enzalutamide blocks prostate cancer AR signaling induced by osteoblast-generated androgen. Enzalutamide is an effective and specific androgen antagonist that blocks three AR activation steps: androgen binding to AR, translocation of the androgen-AR complex to the nucleus, and the association of the androgen-AR complex to AREs. To demonstrate the specificity of DHEA-treated osteoblast conditioned media acting through AR signaling, the ability of enzalutamide to block AR signaling was tested. C4-2B prostate cancer cells were transduced with the tat3-GLuc/DsRed lentivirus combination and treated with and without 1 mM enzalutamide daily, as well as 100 nM DHEA conditioned media, 1 mM DHEA conditioned media, or ethanol vehicle control. Enzalutamide significantly blocked AR signaling of cells treated with 100 nM DHEA conditioned media and 1 mM DHEA conditioned media at 48 and 72 hours. These data indicate specific AR signaling activation of prostate cancer cells by osteoblast-generated androgens.

Conditioned media of osteoblasts treated with DHEA increase prostate PSA production and cell number. The ability of osteoblast-generated androgens to stimulate PSA production by LNCaP and C4-2B cells was tested. The prostate cancer cells were transduced with the DsRed lentivirus to monitor cell number and treated with 100 nM DHEA CM or 100 nM DHEA, 1 mM DHEA CM, or 1 mM DHEA, and compared with EtOH CM and an ethanol vehicle control. Media were collected at 48 and 72 hours. LNCaP and C4-2B showed a marked increase in PSA production in both DHEA CM concentrations. Although PSA did not increase with DHEA direct treatment in the LNCaP cells, it did increase in the C4-2B cells compared with vehicle controls.  Prostate cancer cell growth also responded to osteoblast-generated androgens. Prostate cancer cells were transduced with the DsRed lentivirus and treated with 100 nM DHEA CM or 100 nM DHEA, 1 mM DHEA CM or 1 mM DHEA, and compared with EtOH CM and an ethanol vehicle control. DsRed fluorescence, as a marker of cell number, was measured by fluorescence microscopy and reported as percent culture confluence after 3 and 6 days of culture. Treatment with 100 nM DHEA CM and 1 mM DHEA CM compared with EtOH CM increased cell number in LNCaP and C4-2B cells. The increase was blocked with daily 1 mM enzalutamide treatment, except in C4-2B cells with the 1 mM DHEA CM treatment. The response to DHEA CM compared to direct DHEA treatment differed among cells. In LNCaP cells, the growth response of the 1 mM DHEA CM treatment was greater than the 1 mM DHEA treatment; no difference was detected with the 100 nM treatment groups. In C4-2B cells, 100 nM DHEA CM increased cell number compared with 100 nM DHEA treatment. However, the reverse was true with the higher 1 mM DHEA direct treatment compared with 1 mM DHEA CM.  DHEA does not activate osteoblast AR signaling. The concentration of T generated by conversion of the lowest DHEA concentration in osteoblasts would be expected to activate androgen signaling, as the equilibrium dissociation constant of the AR for T is 0.2 nM. It has been reported that AR is expressed in osteoblasts, osteocytes, osteoclasts, and many other cell types present in the bone microenvironment. We confirmed that AR is expressed in murine

osteoblast cultures (data not shown). When tat3-GLuc/DsRed transduced osteoblasts were treated with R1881, a modest increase in GLuc was detected. However, DHEA at 100 nM and 1 mM did not increase GLuc expression.  Discussion A novel and unreported discovery that the osteoblast generates androgens from the adrenal steroid precursor DHEA is now reported. This finding represents another example that the skeleton is a true hormone-producing organ. It remains unclear the extent to which the skeleton contributes to circulating androgens, but the concentration of testosterone generated is sufficient to activate AR signaling locally. Osteoblasts may therefore represent an essential source of androgens to fuel prostate cancer bone metastases, complementing or fulfilling androgen production when intratumoral androgen generation by prostate cancer cells may be limited or absent. The affinity of prostate cancer cells to the skeleton is a phenomenon that is unique compared with many other types of cancer. The bone microenvironment creating a rich source of androgens is a plausible explanation for prostate cancer's affinity toward invasion and growth in the skeleton.  The intratumoral generation of androgens is an important mechanism of CRPC progression. However, the frequency and degree in which this phenomenon occurs, especially in bone metastasis, are unknown. Variability in intratumoral androgen production is due to inherited genetic variation and changes in steroidogenesis enzyme expression during carcinogenesis.  The four prostate cancer cells reported here represent examples of such variability, as each has unique androgen-generating

characteristics. Although C4-2B was the only cell line that generated DHT, it is likely that intratumoral generation of T without DHT is sufficient to direct CRPC growth. The clinical relevance is that in early bone metastasis, when single or clusters of prostate cancer cells first invade bone, the shear larger number of osteoblasts would contribute to more local androgen production than the prostate cancer cells. As bone metastasis progresses, the contribution of prostate cancer-generated androgens would then depend not only on cell numbers but also on the capacity of these prostate cancer cells to generate androgens.  To investigate how osteoblast-generated androgens contribute to prostate cancer AR signaling and growth, a strategy was selected in which CM from osteoblasts after DHEA treatment was compared with the direct treatment of DHEA. Since osteoblasts did not completely metabolize all DHEA, and androstene-diol and androstenedione intermediates were also present in the CM, these substrates likely contributed to the intratumoral generation of androgens by prostate cancer cells. However, since enzymatic conversion of these substrates by the prostate cancer cells takes time, the greater increase in AR signaling with the CM at the earlier time points is due to osteoblast-generated testosterone.  Although osteoblast-generated androgens, as reported here, likely contribute to prostate cancer expansion in bone, other mechanisms of prostate cancer regulation by osteoblasts have been reported. In one report, co-culture with the pre-osteoblast cell line MC3T3 accentuated the DHT-regulated increase in MDA-PCa-2b prostate cancer cell numbers. CM from MC3T3 cells also increased the expression of AR and the steroidogenesis enzymes HSD3B1, AKR1C3, and SRD5A1 in the CRPC cell line LNCaP-19, leading to an increase in intratumoral androgen production and a possible increase in AR sensitivity. Furthermore, the CM of human primary osteoblast cultures was reported to increase PSA production of LNCaP cells in the absence of steroid treatment. Although a similar result was not found in the data presented here, this may suggest differences between human and mouse primary osteoblast cultures.  The LNCaP and C4-2B prostate cancer cells were selected for further study because of the responsiveness to osteoblast-generated androgens. They were also selected for their dissimilarities in androgen production. Although LNCaP cells had a comparable ability to generate testosterone as osteoblasts, the generation of testosterone did not keep pace with testosterone present in the osteoblast CM. The LNCaP prostate cancer cell line demonstrated greater AR signaling, PSA secretion, and cell numbers with DHEA CM treatments compared with DHEA added directly to the culture media. C4-2B cells, however, displayed different kinetics to osteoblast CM. At earlier time points and with the 100 nM CM treatment, there was a trend for greater AR signaling, PSA production, and cell growth. However, C4-2B AR signaling activation at later time points and at the higher 1 mM DHEA direct treatment outpaced the androgen present in osteoblast CM. This was likely because of the robust conversion of DHEA to testosterone and especially DHT in this cell line. Both cell lines demonstrated a rapid increase in PSA production with the DHEA CM treatments since PSA is a robust, early indicator of AR activation, as previously reported. In contrast, the increase in cell numbers with the DHEA CM treatments is a confirmatory but slower sign of androgen action.  The effects of DHEA and R1881 on AR signaling were also investigated in osteoblasts. Despite osteoblasts generating T from DHEA, AR signaling was not increased compared with vehicle control. Although the concentration of T was sufficient for AR binding, the absence of DHT in the CM of DHEA-treated osteoblasts was a possible contributor. Osteoblasts lack the expression of Srd5a2 that encodes an enzyme with an affinity for T that is 14 to 20 times greater than the enzyme encoded by Srdr5a1. The kinetics of the enzyme encoded by Srd5a3 are unknown. R1881 did increase AR signaling modestly above the vehicle control. These data indicate that the murine osteoblasts harvested from the ends of long bones, specifically the epiphyseal and metaphyseal regions, are not highly sensitive to androgens, despite AR expression. Although osteoblasts have been reported to be targets of androgens, this is not true with osteoblasts in all skeletal compartments. The skeletal phenotype of osteoblast-targeted genetic deletion of Ar has been reported by a number of groups. The consensus among these reports is that trabecular bone but not cortical bone osteoblasts are sensitive to AR actions in both sexes. Because at least a partial response to R1881 was detected, it is likely that the osteoblasts harvested and reported here are a mixture of cortical and trabecular osteoblasts.  An unexpected finding is that only a single 3bHSD enzyme isoform was expressed in mouse osteoblasts and human bone. The 3bHSD7 enzyme may, therefore, serve as a unique drug target to block osteoblast androgen production and prostate cancer bone metastasis in CRPC. Targeting this isoenzyme, which has more tissue-selective expression, would be expected to have fewer adverse effects than targeting other proteins, such as AR, which has more global expression. Mice engineered for Hsd3b7 inactivation die of hepatic failure due to the participation of 3bHSD7 in hepatic bile acid synthesis. However, most of these mice, when maintained on vitamin and bile acid supplements, had a normal life span. Mutations in human HSD3B7 cause

congenital defects in bile acid synthesis. While HSD3B1, another 3bHSD isoenzyme gene, participates in the resistance to androgen-deprivation therapy in prostate cancer patients, a role for HSD3B7 in prostate cancer or the skeleton has not been reported.  During the initial invasion of prostate cancer cells to bone, the osteoblast may be the principal source of androgens. This hypothesis has not been directly tested because clinical trials have not been designed to address this question. The pivotal clinical trials evaluating the androgen synthesis inhibitor abiraterone acetate and the androgen receptor antagonist enzalutamide reported an increase in overall survival and clinical progression-free survival when combined with ADT and compared with ADT alone in patients with metastatic prostate cancer, most of whom had bone metastasis. However, these studies combined the radiographic progression of bone metastasis with other criteria for progression, such as symptomatic skeletal events and progression of soft-tissue tumors. Data reporting solely radiographic progression of bone metastases are unavailable. The results of these clinical trials do not illuminate the extent to which osteoblast-generated androgens promote bone metastasis. Although a separate clinical study reported that abiraterone acetate reduced androgen concentrations in bone marrow collected from men with prostate cancer bone metastases, the individual contributions of the prostate cancer cells and osteoblasts to androgen production remain unclear.  Although estrogens contribute to prostate cancer progression, neither expression of the Cyp19a1 gene that encodes for aromatase nor estradiol in CM was detected in murine osteoblasts. A small amount of CYP19A1 was reported in human iliac bone biopsy samples. These human samples were not a pure osteoblast population, and other cell types were likely present that included bone marrow adipocytes that express CYP19A1.  This report also has implications for skeletal development during adrenarche. Adrenarche commences between the ages of 5 and 8 years in girls and boys and is the period when the adrenal zona reticularis initiates secretion of DHEA and 11-oxygenated C19 steroids. Select tissues convert adrenal DHEA to androgens, including the pubic hair follicles, sweat glands, and the liver. While significant effects of androgens on the skeleton occur during puberty, bone maturation begins during adrenarche before the onset of puberty despite the lack of adequate gonadal T production, possibly due to the intracrine generation of sex steroids from adrenal-derived precursors. Although circulating adrenal 11-ketotestosterone and other androgens are responsible for the androgenic manifestations of normal and premature adrenarche, the osteoblast may be central to local generation of skeletal androgens and subsequent conversion to sex steroids from DHEA before the start of puberty. Local generation of androgens and estrogens may also serve as a protective mechanism to mitigate bone loss during male and female hypogonadism. At the cellular level, T increases osteoblast proliferation and osteocyte function.  We now propose a novel model in which the osteoblast receives adrenal precursor steroids and metabolizes these into androgenic prostate cancer growth factors. This model implies that targeting osteoblast steroidogenic enzymes might be an effective treatment for prostate cancer bone metastases.

Journal of Bone and Mineral Research  MOON ET AL.

52. Chiang C, Chiu M, Moore AJ, et al. Mineralization and bone resorption
are regulated by the androgen receptor in male mice. J Bone Miner
Res. 2009;24(4):621-631.
53. Maatta JA, Buki KG, Ivaska KK, et al. Inactivation of the androgen
receptor in bone-forming cells leads to trabecular bone loss in adult
female mice. BoneKEy Rep. 2013;2:440.
54. Sinnesael M, Claessens F, Laurent M, et al. Androgen receptor (AR) in
osteocytes is important for the maintenance of male skeletal integ-
rity: evidence from targeted AR disruption in mouse osteocytes.
J Bone Miner Res. 2012;27(12):2535-2543.
55. Shea HC, Head DD, Setchell KD, Russell DW. Analysis of HSD3B7
knockout mice reveals that a 3a-hydroxyl stereochemistry is required
for bile acid function. Proc Natl Acad Sci U S A. 2007;104(28):11526-
11533.
56. Schwarz M, Wright AC, Davis DL, Nazer H, Bjorkhem I, Russell DW. The
bile acid synthetic gene 3b-hydroxy-D5-C27-steroid oxidoreductase is
mutated in progressive intrahepatic cholestasis. J Clin Invest. 2000;
106(9):1175-1184.
57. Cheng JB, Jacquemin E, Gerhardt M, et al. Molecular genetics of 3b-
hydroxy-D5-C27-steroid oxidoreductase deficiency in 16 patients
with loss of bile acid synthesis and liver disease. J Clin Endocrinol
Metab. 2003;88(4):1833-1841.
58. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic
acid for treatment of bone metastases in men with castration-
resistant prostate cancer: a randomised, double-blind study. Lancet.
2011;377(9768):813-822.
59. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard
first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;
381(2):121-131.
60. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a random-
ized, phase III study of androgen deprivation therapy with enzaluta-
mide or placebo in men with metastatic hormone-sensitive prostate
cancer. J Clin Oncol. 2019;37(32):2974-2986.
61. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone ace-
tate on androgen signaling in castrate-resistant prostate cancer in
bone. J Clin Oncol. 2012;30(6):637-643.
62. Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS,
Abern MR. Estrogens and prostate cancer. Prostate Cancer Prostatic
Dis. 2019;22(2):185-194.
63. Amanatullah DF, Tamaresis JS, Chu P, et al. Local estrogen axis in the
human bone microenvironment regulates estrogen receptor-
positive breast cancer cells. Breast Cancer Res. 2017;19(1):121.
64. Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated
19-carbon
steroids
are
the
dominant
androgens
in
classic
21-hydroxylase deficiency. Eur J Endocrinol. 2016;174(5):601-609.
65. O'Reilly MW, Kempegowda P, Jenkinson C, et al. 11-oxygenated C19
steroids are the predominant androgens in polycystic ovary syn-
drome. J Clin Endocrinol Metab. 2017;102(3):840-848.
66. Sopher AB, Thornton JC, Silfen ME, et al. Prepubertal girls with
premature adrenarche have greater bone mineral content and
density than controls. J Clin Endocrinol Metab. 2001;86(11):5269-
5272.
67. Sopher AB, Jean AM, Zwany SK, et al. Bone age advancement in
prepubertal children with obesity and premature adrenarche: possi-
ble potentiating factors. Obesity (Silver Spring). 2011;19(6):1259-
1264.
68. Utriainen P, Laakso S, Liimatta J, Jaaskelainen J, Voutilainen R. Prema-
ture adrenarche--a common condition with variable presentation.
Horm Res Paediatr. 2015;83(4):221-231.
69. Rege J, Turcu AF, Kasa-Vubu JZ, et al. 11-Ketotestosterone is the dom-
inant circulating bioactive androgen during normal and premature
adrenarche. J Clin Endocrinol Metab. 2018;103(12):4589-4598.
70. Ucer S, Iyer S, Bartell SM, et al. The effects of androgens on murine
cortical bone do not require AR or ERalpha signaling in osteoblasts
and osteoclasts. J Bone Miner Res. 2015;30(7):1138-1149.
Journal of Bone and Mineral Research
OSTEOBLASTS GENERATE TESTOSTERONE 1579 n